Nijmegen-based ScreenPoint Medical has secured €13.6 million in fresh funding to accelerate the development of AI-driven solutions for breast cancer detection and risk assessment.
The round includes €11.9 million from existing investors — Insight Partners and Siemens Healthineers — alongside €1.7 million in non-dilutive research grants.
Scaling AI Across the Breast Cancer Care Continuum
Founded in 2014 by Nico Karssemeijer and Michael Brady as a spin-off from Radboud University Medical Centre, ScreenPoint Medical focuses on applying AI across the full breast imaging workflow.
Its technology is designed to support clinicians in early detection, improve diagnostic consistency, and enable more personalised care.
AI That Supports Radiologists — Not Replaces Them
The company’s flagship product, Transpara, is an AI-powered platform for automated analysis of mammograms, assisting radiologists in both 2D and 3D imaging.
According to ScreenPoint Medical, its AI can:
- Increase cancer detection rates by up to 29%
- Reduce clinician workload
- Improve workflow efficiency in screening programs
The platform has already processed over 12 million mammograms and is deployed in more than 30 countries, serving hospitals, universities, and national screening programs.
Clinical Validation at Scale
ScreenPoint Medical’s technology has also been validated through large-scale clinical research, including results published in The Lancet.
A major randomized controlled trial (MASAI) demonstrated improved cancer detection rates and reduced workload compared to standard screening methods — a key milestone for AI adoption in clinical environments.
Backed to Expand Globally
With the new funding, the company plans to:
- Accelerate product innovation
- Expand into new international markets
- Strengthen its role in personalised and precision medicine
AI’s Role in the Future of Healthcare
As healthcare systems face increasing pressure from rising demand and workforce shortages, AI is becoming a critical layer in diagnostic workflows.
ScreenPoint Medical is positioning itself at the forefront of this shift — not by replacing clinicians, but by augmenting their ability to detect disease earlier, faster, and more accurately.
